Search

ENPNewswire-January 7, 2025--argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference (C)2025 ENPublishing - http://www.enpublishing.co.uk Release date- 06012025 - Amsterdam, The Netherlands - argenx (Euronext & Nasdaq: ARGX), a [...]

ENPNewswire-November 21, 2024--argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 20112024 - Amsterdam, The Netherlands - argenx SE (Euronext & Nasdaq: [...]

ENPNewswire-November 12, 2024--argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 11112024 - Amsterdam, The Netherlands - [...]

ENPNewswire-November 1, 2024--argenx Reports Third Quarter 2024 Financial Results and Provides Business Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 31102024 - Amsterdam, The Netherlands - argenx SE (Euronext & Nasdaq: [...]

ENPNewswire-October 25, 2024--argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 24102024 - Amsterdam, The Netherlands - argenx [...]

ENPNewswire-August 29, 2024--argenx to Present at Upcoming Investor Conferences (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 28082024 - Amsterdam, The Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company [...]

August 28, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

ENPNewswire-July 26, 2024--argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 25072024 - Amsterdam, The Netherlands - argenx SE (Euronext [...]

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART [sup. (R) ] Hytrulo following June 21 [sup. st ] FDA approval On track to [...]

July 18, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC [...]

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with [...]

VYVGART(R) Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years [...]

ENPNewswire-June 18, 2024--argenx to unveil its Vision 2030, Taking Breakthrough Science to 50,000 Patients during its Upcoming R&D Day on July 16, 2024 (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 17062024 [...]

R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline [...]

ENPNewswire-June 5, 2024--argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 04062024 - Amsterdam, The Netherlands - argenx (Euronext & Nasdaq: ARGX), [...]

June 4, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

ENPNewswire-May 10, 2024--argenx Reports First Quarter 2024 Financial Results and Provides Business Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 09052024 - Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: [...]

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for [...]

May 7, 2024 - 5:30pm ET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe [...]

May 7, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

May 2, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

ADHERE data show VYVGART (R) Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over [...]

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consistency across efficacy and biomarker measures March 27, 2024, 7:00 AM CET Amsterdam, the Netherlands [...]

March 26, 2024 Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today [...]

VYVGART (R) now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents first global approval for VYVGART in ITP March 26, [...]

ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART [...]

ENPNewswire-March 1, 2024--argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 29022024 - Amsterdam - argenx SE (Euronext & Nasdaq: [...]

$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART(R) Hytrulo for CIDP accepted for priority review by FDA with PDUFA target [...]

February 26, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

February 22, 2024 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART [sup. (R) ] Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to [...]

Availability of VYVGART [sup. (R) ] and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, [...]

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART [sup. (R) ] Hytrulo for CIDP with priority review voucher (PRV); if approved, [...]

ENPNewswire-January 3, 2024--argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 02012024 - Amsterdam - argenx (Euronext & Nasdaq: ARGX), a global immunology [...]

Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van [...]

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, 2023, at [...]

Study did not meet primary or secondary endpoints Favorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm [...]

(GlobeNewswire) - VYVGART is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to [...]

VYVGART(R) is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to enable broad [...]

November 1, 2023 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

$329 million in third quarter global net product sales On track to submit VYVGART[sup.(R)] Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet [...]

October 24, 2023 Amsterdam, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced [...]

VYVGART [sup. â'? ] is the first-and-only neonatal Fc receptor ( FcRn ) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p Amsterdam, [...]

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administration European Commission (EC) decision [...]

August 30 , 202 3 Amsterdam , the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune [...]

$269 million in second quarter VYVGART(R) (efgartigimod alfa-fcab) global net product sales VYVGART(R) Hytrulo now available in the U.S. with first vials shipped in July Global VYVGART expansion continued with [...]

Regulated information - Inside i nformation July 24, 2023, 4 : 30 PM ET July 24, 2023, 10 : 30 PM CET Amsterdam, the Netherlands -- argenx SE (Euronext & [...]

July 20 , 202 3 Amsterdam , the Netherlands - argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune [...]

Regulated information -- Inside information July 19, 2023 , 11:58 PM C ET July 19, 2023 , 5:58 PM ET Amsterdam , the Netherlands -- argenx SE (Euronext & Nasdaq: [...]